How many FDA actions does Argus HQ track for Ascend Laboratories, LLC?

3 total: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Ascend Laboratories, LLC?

June 17, 2026. Argus HQ ingests new FDA enforcement records daily.

Has Ascend Laboratories, LLC had product recalls?

Yes, 3 recalls on file. See the full history below for each one.

Is this FDA enforcement data for Ascend Laboratories, LLC official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Ascend Laboratories, LLC's Complete FDA Record

FDA action counts

Total FDA actions	3
Warning letters	0
Recalls	3
Approval records	0
Form 483 inspection citations	0
Most recent action	June 17, 2026

Key takeaway: Argus HQ has recorded 3 FDA events for Ascend Laboratories, LLC: 0 warning letters, 3 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-05-20 to 2026-06-17. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Enforcement history

On 2026-05-20, Argus HQ recorded a FDA recall for Ascend Laboratories, LLC, rated "high" severity in Argus HQ's classification: Ascend Laboratories, LLC — Class II recall: Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-10, Argus HQ recorded a FDA recall for Ascend Laboratories, LLC, rated "high" severity in Argus HQ's classification: Ascend Laboratories, LLC — Class II recall: Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle,… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-17, Argus HQ recorded a FDA recall for Ascend Laboratories, LLC, rated "high" severity in Argus HQ's classification: Ascend Laboratories, LLC — Class II recall: Minocycline Hydrochloride Extended-Release Tablets, USP, 115 mg, 30-count bottle… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. In total, Ascend Laboratories, LLC has 3 FDA events on file with Argus HQ across the sources Argus HQ currently tracks (FDA Warning Letters, recalls, drug/biologic approvals, and Form 483 inspection observations). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Ascend Laboratories, LLC has 3 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event.

Frequently asked questions

How many FDA actions does Argus HQ track for Ascend Laboratories, LLC?: 3 total: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for Ascend Laboratories, LLC?: June 17, 2026. Argus HQ ingests new FDA enforcement records daily.
Has Ascend Laboratories, LLC had product recalls?: Yes, 3 recalls on file. See the full history below for each one.
Is this FDA enforcement data for Ascend Laboratories, LLC official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Ascend Laboratories, LLC's Complete FDA Record. Digital Empire LLC. Retrieved from https://argushq.ai/company/ascend-laboratories-llc

MLA

"Ascend Laboratories, LLC's Complete FDA Record." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/ascend-laboratories-llc.

Chicago

Argus HQ Research. "Ascend Laboratories, LLC's Complete FDA Record." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/ascend-laboratories-llc.

BibTeX

@misc{argushq_argushq_ai_company_ascend_laboratories_llc_2026,
  title = {Ascend Laboratories, LLC's Complete FDA Record},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/ascend-laboratories-llc},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗